CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy

Overview of attention for article published in Journal of Clinical Oncology, March 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 9 news outlets
blogs: 1 blog

twitter: 42 X users
reddit: 1 Redditor

Readers on

mendeley: 52 Mendeley

So far, Altmetric has seen 1 blog post.

RCT: No improvement in OS with atezolizumab plus cabozantinib vs. docetaxel in metastatic NSCLC post Anti-PD-L1/PD-1 therapy

SPECIALTIES, 28 Apr 2024

In a phase III trial, 366 patients with metastatic non-small cell lung cancer (NSCLC) were evaluated to determine the efficacy…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.